» Articles » PMID: 24361249

Association Between Race and Survival of Patients with Non--small-cell Lung Cancer in the United States Veterans Affairs Population

Overview
Publisher Elsevier
Date 2013 Dec 24
PMID 24361249
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Racial disparities in outcomes of non-small-cell lung cancer (NSCLC) patients in the United States are well documented. A retrospective analysis of patients in the Veterans Affairs Central Cancer Registry was conducted to determine whether similar disparities exist in a population with a single-payer, accessible health care system.

Patients And Methods: Demographic data of patients diagnosed with NSCLC between January 1995 and February 2009 were analyzed using Kruskal-Wallis test or the χ(2) test. Multivariate Cox proportional hazards regression analysis was used to compare survival among races.

Results: Of the 82,414 patients, 98% were male, 82% had a smoking history, and 81% were Caucasian. Caucasian individuals had better prognostic features compared with African-American individuals (stage I/II [24% vs. 21%]; Grade I/II [21% vs. 17%]). A larger proportion of Caucasian compared with African-American individuals received stage-appropriate treatment (surgery for stage I [48% vs. 41%; P < .001]; chemotherapy for stage IV [18% vs. 16%; P = .003]). African-American individuals had a lower risk of mortality compared with Caucasian individuals (hazard ratio, 0.94; 95% confidence interval, 0.92-0.96).

Conclusion: Although African-American patients had a higher stage and grade of NSCLC, they had a better overall survival than Caucasian patients. In a single-payer system with accessible health care, previously described racial differences in lung cancer outcomes were not observed.

Citing Articles

Lung Cancer Survival Trends in the Veterans Health Administration.

Moghanaki D, Taylor J, Bryant A, Vitzthum L, Sebastian N, Gutman D Clin Lung Cancer. 2024; 25(3):225-232.

PMID: 38553325 PMC: 11098707. DOI: 10.1016/j.cllc.2024.02.009.


What health inequalities exist in access to, outcomes from and experience of treatment for lung cancer? A scoping review.

Lennox L, Lambe K, Hindocha C, Coronini-Cronberg S BMJ Open. 2023; 13(11):e077610.

PMID: 37918927 PMC: 10626811. DOI: 10.1136/bmjopen-2023-077610.


Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.

Moore A, Nooruddin Z, Reveles K, Koeller J, Whitehead J, Franklin K Oncologist. 2023; 28(9):804-811.

PMID: 37335901 PMC: 10485300. DOI: 10.1093/oncolo/oyad172.


Timely Curative Treatment and Overall Mortality Among Veterans With Stage I NSCLC.

Sanchez R, Vaughan Sarrazin M, Hoffman R JTO Clin Res Rep. 2023; 4(2):100455.

PMID: 36908685 PMC: 9995692. DOI: 10.1016/j.jtocrr.2022.100455.


Oncology distress screening within predominately Black Veterans: Outcomes on supportive care utilization, hospitalizations, and mortality.

Azizoddin D, Allsop M, Farah S, Salim F, Hauser J, Baltazar A Cancer Med. 2022; 12(7):8629-8638.

PMID: 36573460 PMC: 10134375. DOI: 10.1002/cam4.5560.